NDLI: Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer

Content Provider	Springer Nature : BioMed Central
Author	Nguyen Van Long, Flora Lardy-Cleaud, Audrey Carène, Dimitri Rossoni, Caroline Catez, Frédéric Rollet, Paul Pion, Nathalie Monchiet, Déborah Dolbeau, Agathe Martin, Marjorie Simioni, Valentin Bray, Susan Le Beherec, Doris Mosele, Fernanda Bouakka, Ibrahim Colombe-Vermorel, Amélie Odeyer, Laetitia Diot, Alexandra Jordan, Lee B. Thompson, Alastair M. Jamen, Françoise Dubois, Thierry Chabaud, Sylvie Michiels, Stefan Treilleux, Isabelle Bourdon, Jean-Christophe Pérol, David Puisieux, Alain André, Fabrice Diaz, Jean-Jacques Marcel, Virginie
Abstract	Background A current critical need remains in the identification of prognostic and predictive markers in early breast cancer. It appears that a distinctive trait of cancer cells is their addiction to hyperactivation of ribosome biogenesis. Thus, ribosome biogenesis might be an innovative source of biomarkers that remains to be evaluated. Methods Here, fibrillarin (FBL) was used as a surrogate marker of ribosome biogenesis due to its essential role in the early steps of ribosome biogenesis and its association with poor prognosis in breast cancer when overexpressed. Using 3,275 non-metastatic primary breast tumors, we analysed FBL mRNA expression levels and protein nucleolar organisation. Usage of TCGA dataset allowed transcriptomic comparison between the different FBL expression levels-related breast tumours. Results We unexpectedly discovered that in addition to breast tumours expressing high level of FBL, about 10% of the breast tumors express low level of FBL. A correlation between low FBL mRNA level and lack of FBL detection at protein level using immunohistochemistry was observed. Interestingly, multivariate analyses revealed that these low FBL tumors displayed poor outcome compared to current clinical gold standards. Transcriptomic data revealed that FBL expression is proportionally associated with distinct amount of ribosomes, low FBL level being associated with low amount of ribosomes. Moreover, the molecular programs supported by low and high FBL expressing tumors were distinct. Conclusion Altogether, we identified FBL as a powerful ribosome biogenesis-related independent marker of breast cancer outcome. Surprisingly we unveil a dual association of the ribosome biogenesis FBL factor with prognosis. These data suggest that hyper- but also hypo-activation of ribosome biogenesis are molecular traits of distinct tumors.
Related Links	https://bmccancer.biomedcentral.com/counter/pdf/10.1186/s12885-022-09552-x.pdf
Ending Page	12
Page Count	12
Starting Page	1
File Format	HTM / HTML
ISSN	14712407
DOI	10.1186/s12885-022-09552-x
Journal	BMC Cancer
Issue Number	1
Volume Number	22
Language	English
Publisher	BioMed Central
Publisher Date	2022-05-11
Access Restriction	Open
Subject Keyword	Cancer Research Oncology Surgical Oncology Health Promotion and Disease Prevention Biomedicine Medicine Public Health Fibrillarin Ribosome biogenesis rRNA 2’O-ribose methylation complex AgNOR Breast cancer Medicine/Public Health
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology Genetics
Journal Impact Factor	3.4/2023
5-Year Journal Impact Factor	3.8/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Decelerated DNA methylation age predicts poor prognosis of breast cancer

DNA methylation gene-based models indicating independent poor outcome in prostate cancer

Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer

RECK is not an independent prognostic marker for breast cancer

High baseline Tie1 level predicts poor survival in metastatic breast cancer

Promoter methylation-associated loss of ID4expression is a marker of tumour recurrence in human breast cancer

Methylation signature of lymph node metastases in breast cancer patients

PIK3R1 underexpression is an independent prognostic marker in breast cancer

BRCA2 carriers with male breast cancer show elevated tumour methylation

Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer

Similar Documents

Decelerated DNA methylation age predicts poor prognosis of breast cancer

DNA methylation gene-based models indicating independent poor outcome in prostate cancer

Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer

RECK is not an independent prognostic marker for breast cancer

High baseline Tie1 level predicts poor survival in metastatic breast cancer

Promoter methylation-associated loss of ID4expression is a marker of tumour recurrence in human breast cancer

Methylation signature of lymph node metastases in breast cancer patients

PIK3R1 underexpression is an independent prognostic marker in breast cancer

BRCA2 carriers with male breast cancer show elevated tumour methylation

Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer